You have reached the HIVandHepatitis.com legacy site. Please visit our new site at hivandhepatitis.com
and Hepatitis.com Coverage of the
61st Annual Meeting of the American Association for the Study of Liver Diseases (AASLD 2010)
October 29 - November 2, 2010, Boston, MA
IL28B Gene Patterns and Liver Transplant Outcomes in Hepatitis C Patients
Single nucleotide polymorphisms, or SNPs, are substitutions of a single nucleotide building block at a specific position in a DNA chain. A number of SNPs -- most often12979860 -- near the IL28B gene have been implicated. This gene encodes instructions for making interferon lambda, or interleukin 28.
carries 2 copies of every gene, one from each parent. The IL28B rs12979860
SNP has 2 variations, or alleles, "C" and "T." Hepatitis
C patients with the homozygous or matching C/C pattern (2 copies of
the "C" allele) are most likely to spontaneously clear HCV
and have the best response to interferon-based therapy. People with
the T/T pattern (2 "T" alleles) have the least favorable response,
while those with the heterozygous or mixed C/T pattern (1 copy of each
variation) fall in between.
"Recipient IL28B genotype is associated with more rapid histological recurrence of HCV," the researchers concluded. "Recipient and donor liver IL28B genotype are strongly and independently associated with interferon-based treatment response in patients post-[transplant]."
"The data suggest that C/C donor livers might be preferentially allocated to patients with HCV infection," they recommended.
Spanish study also looked at the relationship between IL28B variations
and liver transplant outcomes.
Before transplantation, everyone with the protective rs12979860 or rs8099917 pattern responded to treatment (HCV RNA decline of at least 2 log by week 12), as did 77% of patients with the mixed rs12979860 and 62% with the mixed rs8099917 patterns.
After transplantation, the likelihood of treatment response was higher among individuals who received new livers from donors with protective rs12979860 or rs8099917 patterns (82% and 73% response, respectively).
There were 3 pre-treatment responders who became post-treatment non-responders, and 4 people who changed from non-responders to responders. These 4 did not carry protective IL28B patterns themselves, but became responders after receiving donor livers that did.
This research team likewise suggested that, "the allocation of [liver] grafts with a favorable genetic background could improve sensitivity to therapy after liver transplantation."
MR Charlton, AJ Thompson, BJ Veldt, and others. IL28B polymorphisms are associated with histological recurrence and treatment response following liver transplantation in patients with HCV with HCV Infection. 61st Annual Meeting of the American Association for the Study of Liver Diseases (AASLD 2010). Boston, October 29-November 2, 2010. Abstract 1.
M Coto-Llerena, S Perez-del-Pulga, G Crespo, and others. IL28B polymorphisms may improve response to hepatitis C therapy after liver transplantation. 61st Annual Meeting of the American Association for the Study of Liver Diseases (AASLD 2010). Boston, October 29-November 2, 2010. Abstract 1140.